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INTRODUCTION
The introduction of biologic immunomodulators, in par-
ticular antibodies targeted against tumor necrosis factor al-
pha (TNF-alpha), has revolutionized treatment of Crohn’s 
disease. However, this comes at the expense of a higher risk 
for opportunistic infections due to a generalized immuno-
suppressive effect. Bacterial and opportunistic infections are 
well-known complications of anti-TNF agents.1,2 Nocardia 
has been reported rarely among patients on anti-TNF agents.3 
TNF plays a role in the clearance of norcardia in animal 
models.4 Immunosuppression, anti-TNF treatment in particu-
lar, may favor growth and dissemination of nocardia. Pulmo-
nary and cutaneous nocardiosis has been reported in Crohn’s 
disease patients on infliximab.5,6 Nocardiosis has been re-
ported with adalimumab therapy in rheumatoid arthritis pa-
tients.7,8 Our search did not reveal any cases of nocardiosis 
while on adalimumab therapy in Crohn’s disease patients. 
Crohn’s disease patients receiving biologic agents, in 
particular, tumor necrosis factor (TNF)-alpha inhibitors 
are immunosuppressed and are prone to develop oppor-
tunistic infections. We report a rare case of primary cuta-
neous nocardiosis in an immunocompromised patient on 
chronic anti-TNF for underlying severe Crohn’s disease.
CASE REPORT 
A 36-year-old Caucasian gentleman with a history of 
Crohn’s disease treated with adalimumab presented with a 
cellulitis-like rash on his forehead (Figure 1). Five weeks pre-
viously, he had struck his forehead on a construction pole, 
sustaining a laceration which required sutures. On presenta-
tion, he had developed purulent discharge from the lacera-
tion site, and he was started on doxycycline. After completing 
antibiotic treatment, he was seen by a dermatologist due to 
persistent rash and a punch biopsy was taken from the area.
Figure 1. Cellulitis-like rash with draining and crusting.
Histological examination of the biopsy showed granu-
lomatous inflammation thought to be related to a foreign 
body. The lesion worsened with increasing pain, pruri-
tus, erythema, and development of a furuncle with drain-
age of yellow purulent material. A swab was sent for aero-
bic culture which grew coagulase negative staphylococci. 
Viral and fungal cultures from this lesion were negative. 
Over the next several weeks, the lesion continued to worsen, 
growing in size and becoming more painful. The adalimumab 
therapy was stopped and pyoderma gangrenosum was consid-
ered due to the patient’s underlying Crohn’s disease. The patient 
subsequently was admitted due to uncontrolled pain, and pro-
gression of his forehead lesion. A comprehensive work-up for 
human immunodeficiency virus, syphilis, tuberculosis, hepati-
tis, antinuclear antibody, rheumatoid factor, anti-cyclic citrulli-
nated peptide, and serum protein electrophoresis were negative. 
Blood (bacterial and fungal), urine, and sputum cultures were 
negative.  Chest x-ray was negative. With IV antibiotics, there 
was some improvement in the forehead rash and the patient 
was discharged on oral antibiotics. He also was started on dap-
sone and clobetasol for treatment of pyoderma gangrenosum. 
One week later, cultures from his biopsy grew Nocardia arthri-
tidis (Figure 2). He was started on trimethoprim-sulfamethoxa-
zole daily with follow-up with an infectious disease specialist. 
His rash improved significantly after a few weeks of treatment.
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Figure 2. Nocardia asteroids staining and culture.
Figure 2. Nocardia asteroids staining and culture.
 
DISCUSSION
Human nocardiosis is caused by nocardia species which is 
an ubiquitous soil inhabiting bacteria and considered an op-
portunistic pathogen.8 It can affect the skin and classically dis-
seminate to involve the lungs and brain. It is a difficult infection 
to treat and carries high mortality if disseminated.9 Nocar-
diosis has been well known to affect AIDS patients, transplant 
recipients, and long term corticosteroid treated individuals. 
Now, it is being recognized increasingly in immunosuppressed 
patients on anti-TNF agents. Previous use of corticosteroids 
has been identified as a risk factor, as noted in our case, and 
was present in more than 50% of cases in earlier studies.10 
Early diagnosis is essential and norcardia should be con-
sidered in the differential diagnosis of any patient present-
ing with draining skin lesion or painful rash who is receiving 
anti-TNF agents or has in the recent past. Anti-TNF therapy 
doubles the risk of opportunistic infections in inflammatory 
bowel disease patients.9,10 This underscores the importance of 
adherence to guidelines for their prevention and management. 
A high level of vigilance and scrutiny in examination and fol-
low up are highly recommended for this group of patients.
CONCLUSION
 A high level of suspicion must be enforced when patients re-
ceiving TNF-alpha inhibitors present with skin manifestations, 
in particular, cellulitis-rash or draining lesion. Early identifica-
tion and treatment of nocardia is pivotal to prevent disseminat-
ed disease and mortality.
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